Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies? - Test2 - elhamkhani - TriplyDB

Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

http://www.wikidata.org/entity/Q34335207

about

Pretargeted radioimmunotherapy for hematologic and other malignancies Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.

P2860

Q34113941-1A821335-4C1D-4D34-814C-77D032C07D89 Q34543794-8F1CE9FD-A62A-4C97-99F2-4D2B0B921CFB Q35815494-EF0A2783-6C14-405B-A7BE-B2665FB50D7D

P2860

Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

http://www.wikidata.org/entity/Q34335207

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

@ast

Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

@en

Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

@nl

type

label

Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

@ast

Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

@en

Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

@nl

prefLabel

Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

@ast

Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

@en

Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

@nl

P1433

Q34335207-9CDF1F2D-0AB5-43C6-943B-527269D07646

P1476

Q34335207-429C2104-556A-4AF7-973C-AA65A3A1FB5C

P2093

Q34335207-0431F79C-242A-424F-B5E2-7BC8726E410E

Q34335207-15750D23-CB62-48A1-8F7C-28F4F010E22B

Q34335207-3692535E-74C6-41F1-9A43-C761D8FA17E3

P2860

Q34335207-019A072B-47DE-4938-9D91-F571764F7706

Q34335207-084F860C-B71D-479C-B408-4117CE6946D4

Q34335207-0A954BB3-F23F-4D43-83D9-29BCB85CA83E

Q34335207-0CEC093C-B23C-4F51-A9DD-663D719C341D

Q34335207-0D0A92C3-1401-4094-876E-97FB7777FE2B

Q34335207-10B2BD65-1233-4416-9F2A-A84801CE0D03

Q34335207-141D58CA-501E-4F6B-BE5A-BAB4F7C81573

Q34335207-22CA9E73-B9C0-48F5-9378-82AC2D740184

Q34335207-2E98A319-B349-4C26-B526-6BC825D56A45

Q34335207-2F4C4FAE-2D28-4064-ACC1-BC2F58581E8A

P304

Q34335207-F12E9222-21A0-4EDD-A0CF-5EE9E2B3450F

P31

Q34335207-B1F4B4AD-A464-427D-BE15-BDCD831CD556

P356

Q34335207-04C4A868-C2C5-4FC0-ACBD-F11A8657E58D

P433

Q34335207-AA380005-2F02-4063-9E7C-B7C22A179743

P478

Q34335207-7D304DD9-D639-4D6F-9FF8-B4AF5F0DDC73

P577

Q34335207-DD046E6B-4FD5-4DCC-8035-63BB089B20B0

P698

Q34335207-9E39BDF0-D7AA-47EF-A96B-FE0850DA7951

P932

Q34335207-733335BA-E3E8-4A59-9546-9966A0A2C091

P356

CBR.2007.0523-U

P1433

Cancer Biotherapy and Radiopharmaceuticals

P1476

Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

@en

P2093

Gerald L DeNardo

http://www.w3.org/2001/XMLSchema#string

Rod Balhorn

http://www.w3.org/2001/XMLSchema#string

Sally J DeNardo

http://www.w3.org/2001/XMLSchema#string

P2860

Epidermal growth factor-related peptides and their receptors in human malignancies

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.

Update: affibody molecules for molecular imaging and therapy for cancer.

Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer.

Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results.

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.

P304

383-397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/CBR.2007.0523-U

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18771343

http://www.w3.org/2001/XMLSchema#string

P932

2988689

http://www.w3.org/2001/XMLSchema#string